These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31147392)

  • 1. Lovastatin, not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model.
    Muscas M; Louros SR; Osterweil EK
    eNeuro; 2019; 6(3):. PubMed ID: 31147392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
    Yan QJ; Rammal M; Tranfaglia M; Bauchwitz RP
    Neuropharmacology; 2005 Dec; 49(7):1053-66. PubMed ID: 16054174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.
    Sawicka K; Pyronneau A; Chao M; Bennett MV; Zukin RS
    Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6290-E6297. PubMed ID: 27663742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.
    Osterweil EK; Chuang SC; Chubykin AA; Sidorov M; Bianchi R; Wong RK; Bear MF
    Neuron; 2013 Jan; 77(2):243-50. PubMed ID: 23352161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excessive proteostasis contributes to pathology in fragile X syndrome.
    Louros SR; Seo SS; Maio B; Martinez-Gonzalez C; Gonzalez-Lozano MA; Muscas M; Verity NC; Wills JC; Li KW; Nolan MF; Osterweil EK
    Neuron; 2023 Feb; 111(4):508-525.e7. PubMed ID: 36495869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome.
    Thomson SR; Seo SS; Barnes SA; Louros SR; Muscas M; Dando O; Kirby C; Wyllie DJA; Hardingham GE; Kind PC; Osterweil EK
    Neuron; 2017 Aug; 95(3):550-563.e5. PubMed ID: 28772121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Differential Effect of Lovastatin versus Simvastatin in Neurodevelopmental Disorders.
    Muscas M; Seo SS; Louros SR; Osterweil EK
    eNeuro; 2020; 7(4):. PubMed ID: 32651266
    [No Abstract]   [Full Text] [Related]  

  • 8. Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes.
    Musumeci SA; Calabrese G; Bonaccorso CM; D'Antoni S; Brouwer JR; Bakker CE; Elia M; Ferri R; Nelson DL; Oostra BA; Catania MV
    Exp Neurol; 2007 Jan; 203(1):233-40. PubMed ID: 17007840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
    Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB
    Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice.
    Sidorov MS; Krueger DD; Taylor M; Gisin E; Osterweil EK; Bear MF
    Genes Brain Behav; 2014 Jun; 13(5):451-8. PubMed ID: 24684608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet's signaling cascades as new outcome measures in clinical trials.
    Pellerin D; Çaku A; Fradet M; Bouvier P; Dubé J; Corbin F
    Biomarkers; 2016 Sep; 21(6):497-508. PubMed ID: 27058300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice.
    Chatterjee M; Kurup PK; Lundbye CJ; Hugger Toft AK; Kwon J; Benedict J; Kamceva M; Banke TG; Lombroso PJ
    Neuropharmacology; 2018 Jan; 128():43-53. PubMed ID: 28943283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of three statins at lower maintenance doses.
    Carr-Lopez S; Exstrum T; Morse T; Shepherd M; Bush AC
    Clin Ther; 1999 Feb; 21(2):331-9. PubMed ID: 10211536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Pincus J
    Am J Cardiol; 1998 Aug; 82(3):406-7. PubMed ID: 9708683
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug.
    Cheetham TC; Chan J; Benson V; Richmond C; Levin E; Campen D
    Am J Manag Care; 2005 Sep; 11(9):546-52. PubMed ID: 16159044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
    Çaku A; Pellerin D; Bouvier P; Riou E; Corbin F
    Am J Med Genet A; 2014 Nov; 164A(11):2834-42. PubMed ID: 25258112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
    Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
    Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.